Jasmin Zeindler

Jasmin Zeindler

Auto-generated profile, based on publicly available information

Jasmin Zeindler

Department of General and Visceral Surgery, Kantonsspital Baselland, Liestal, Switzerland

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2019 in The American Journal of Surgery
Verified
Journal Article
Closed access
EMEdin Mujagic
Edin Mujagic
JZJasmin Zeindler
Jasmin Zeindler
MCMichael Coslovsky
Michael Coslovsky
HHHenry Hoffmann
Henry Hoffmann
SSSavas D. Soysal
Savas D. Soysal
WWWalter P. Weber
Walter P. Weber

2 July 2019 in Breast Cancer Research and Treatment
Verified
Journal Article
Closed access
PDF file
JZJasmin Zeindler
Jasmin Zeindler
FAFiorenzo Angehrn
Fiorenzo Angehrn
RDRaoul Droeser
Raoul Droeser
SDSilvio Däster
Silvio Däster
Salvatore PiscuoglioSalvatore Piscuoglio
Salvatore Piscuoglio
SSSavas Deniz Soysal
Savas Deniz Soysal

8 January 2019 in BMC Cancer
Verified
Journal Article
Open access
PDF file
RMRobert Mechera
Robert Mechera
SSSavas D. Soysal
Savas D. Soysal
Salvatore PiscuoglioSalvatore Piscuoglio
Salvatore Piscuoglio
CNCharlotte K Y Ng
Charlotte K Y Ng
JZJasmin Zeindler
Jasmin Zeindler
SMSimone Muenst
Simone Muenst
The Rearranged during Transfection (RET) protein is overexpressed in a subset of Estrogen Receptor (ER) positive breast cancer, with both signalling pathways functionally interacting. This cross-talk plays a pivotal role in the resistance of breast cancer cells to anti-endocrine therapies, and RET expression is assumed to correlate with poor prognosis based on findings in small patient cohorts. The aim of our study was to investigate the impact of RET expression on patient outcome in human breast cancer. We performed an immunohistochemical analysis of RET protein expression on a tissue microarray encompassing 990 breast cancer patients and correlated its expression with clinicopathological parameters and survival data. Expression of RET was detected in 409 out of 990 cases (41.3%). RET and ER expression significantly correlated (p < 0.0001). The Luminal B HER2-positive subtype showed the highest expression rate (48.9%). In univariate and multivariate survival analyses, RET expression had no impact on overall survival. We confirmed the co-expression of RET and ER, but we did not find RET expression to be an independent prognostic factor in human breast cancer. Clinical trials with newly developed RET inhibitors are needed to evaluate if RET inhibition has a beneficial impact on patient survival in ER positive breast cancer.

1 April 2018 in The American Journal of Surgery
Verified
Journal Article
Closed access
EMEdin Mujagic
Edin Mujagic
WMWalter R. Marti
Walter R. Marti
MCMichael Coslovsky
Michael Coslovsky
JZJasmin Zeindler
Jasmin Zeindler
SSSebastian Manuel Staubli
Sebastian Manuel Staubli
WWWalter P. Weber
Walter P. Weber

13 March 2024 in Cancer Medicine
Verified
Journal Article
Open access
JZJasmin Zeindler
Jasmin Zeindler
GHGabriel Fridolin Hess
Gabriel Fridolin Hess
MHMaximilian von Heesen
Maximilian von Heesen
NANoa Aegerter
Noa Aegerter
CRCornelia Reber
Cornelia Reber
OKOtto Kollmar
Otto Kollmar
Background: The incidence of hepatocellular carcinoma (HCC) is increasing in the western world over the past decades. As liver resection (LR) represents one of the most efficient treatment options, advantages of anatomic (ALR) versus non‐anatomic liver resection (NALR) show a lack of consistent evidence. Therefore, the aim of this study was to investigate complications and survival rates after both resection types.Methods: This is a multicentre cohort study using retrospectively and prospectively collected data. We included all patients undergoing LR for HCC between 2009 and 2020 from three specialised centres in Switzerland and Germany. Complication and survival rates after ALR versus NALR were analysed using uni‐ and multivariate Cox regression models.Results: Two hundred and ninety‐eight patients were included. Median follow‐up time was 52.76 months. 164/298 patients (55%) underwent ALR. Significantly more patients with cirrhosis received NALR (n = 94/134; p < 0.001). Complications according to the Clavien Dindo classification were significantly more frequent in the NALR group (p < 0.001). Liver failure occurred in 13% after ALR versus 8% after NALR (p < 0.215). Uni‐ and multivariate cox regression models showed no significant differences between the groups for recurrence free survival (RFS) and overall survival (OS). Furthermore, cirrhosis had no significant impact on OS and RFS.Conclusion: No significant differences on RFS and OS rates could be observed. Post‐operative complications were significantly less frequent in the ALR group while liver specific complications were comparable between both groups. Subgroup analysis showed no significant influence of cirrhosis on the post‐operative outcome of these patients.

1 November 2019 in European Journal of Vascular and Endovascular Surgery
Verified
Journal Article
Closed access
JZJasmin Zeindler
Jasmin Zeindler
SRSabine Richarz
Sabine Richarz
MFMarco Franchin
Marco Franchin
SSSavas D. Soysal
Savas D. Soysal
LGLorenz Gürke
Lorenz Gürke
AIAndrej Isaak
Andrej Isaak